^
    Back
    Association details:
    Biomarker:KIT expression
    Cancer:Endometrial Cancer
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Gastrointestinal Stromal Tumor)
    New
    Excerpt:
    Gleevec is a kinase inhibitor indicated for the treatment of...Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Gynecol Oncol
    Title:

    A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate

    Excerpt:
    A 41-year-old woman suffering HGES, with positive staining for CD117 (c-kit) and large abdominal and retroperitoneal mass progressing after chemotherapy, was treated with Imatinib Mesylate. After 3 months, objective response was documented and radical surgery performed. Two years after surgical intervention, she is currently free of the disease.
    DOI:
    10.1016/j.ygyno.2006.01.024